Table 3 subgroup analysis of the included studies for outcome oligodendrocyte precursor cell counts.

From: Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis

Subgroup Comparisons Effect estimate [95% CI] I2
Overall 34 0.87 [−0.08, 1.83] 92%
Therapeutic regimen
therapeutically 29 1.31 [0.25, 2.37] 93%
Method
PDGFRα 13 2.50 [0.51, 4.49] 94%
  1. The effect estimate was displayed by the standardized mean difference (SMD) and 95% confidence intervals (CIs). No significant differences were found in the subgroup analyses.